Events

Seminar: New Modalities in Neurodegenerative Disease Management – Is Europe Ready to Innovate?
MAY
Tue
13
12:30 - 17:45

This was 9 months ago

Location

Permanent Representation of Estonia to the EU, Brussels

Rue Guimard 11/13, 1040 Brussels, Belgium
Programmes
Health

Estonian Research Council Brussels Office and ScanBalt® are organising a seminar on the 13th of May 2025 to address the pressing need for innovation in the early diagnosis of Alzheimer’s and Parkinson’s disease.

Policymakers, industry experts and academia will collaborate to explore how to bridge policy, technology and healthcare for the future of neurogenerative disease diagnosis and care in Europe.

The seminar (12:30-17:45) will be followed by a networking reception (17:45-18:30).

You can find more information and the registration link here.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.